AstraZeneca, BMS Provide Grant for Diabetes Research Initiative

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-02-05-2014, Volume 10, Issue 2

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides a $5 million grant to the American Diabetes Association.

AstraZeneca and Bristol-Myers Squibb reported that the companies’ US Diabetes Alliance is providing a three-year grant to the American Diabetes Association’s Pathway to Stop Diabetes program. The research initiative provides resources and support for a new generation of diabetes researchers and is designed to generate discoveries through collaboration and radical thinking.

The 2013 Pathway Awards will provide $1.6 million in support for five to seven years for the selected investigators and will fund research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. Nominations included a range of disciplines, including medicine, biology, chemistry, engineering, physics, and mathematics.

Source: Bristol-Myers Squibb